Therapeutic Vaccine Market

SKU: DMPH1542 | Last Updated On: Sep 20 2022 | Available Formats

>Therapeutic Vaccine Market Expected to reach at a high CAGR 12.63% by 2029:

Therapeutic Vaccines Market Analysis is segmented By Type (Antigen Vaccines, Dendritic Cell Vaccine, DNA Vaccine, Tumor Cell Vaccines), By Disease Type (Autoimmune Disease Vaccine, Addiction Vaccine, Neurological Disease Vaccine, Infectious Disease Vaccine, Others), By Technology (Autologous Vaccines, Allogeneic Vaccines), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029.

Therapeutic Vaccine Market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 12.63% during the forecast period (2022-2029).

Therapeutic vaccination is a combination of biologics intended to generate protection against the body's aberrant cells. Therapeutic vaccines can be tailored to specific applications and used to treat disorders and diseases such as cancer, HIV infectious diseases, and Alzheimer's disease. Therapeutic vaccinations aid in treating diseases by activating or strengthening the immune response.

The global therapeutic vaccines market is driven by rising incidences of chronic infectious diseases, cancer, Alzheimer’s disease, etc.

Increasing subsidiaries from government organizations to pharmaceutical companies, especially in health research, is expected to drive the market's growth.

The NIH in the US contributes around the US $30.9 billion annually to health research. In Canada, the Canadian Institute of Health Research (CIHR) and a new Industrial Research Assistance program contribute nearly US$0.76 billion to health research each year. The UK research council contributes US$888 million annually to health research, and such huge contributions would greatly impact the market for therapeutic vaccines.

As regulatory processes become strict and competitive, new products have a major clinical benefit in terms of safety and efficacy or end-result over existing products. This leads to numerous head-to-head experiments between important market products and new products or applicants for late-stage pipelines. For instance, GlobeImmune, a biopharmaceutical company, is continuously working on the development of new vaccine candidates for tuberculosis and oncology. For instance, the current TB vaccine pipeline includes GI-19000, which is in the preclinical stage and GI-6301 for Chordoma Cancer is in Phase-II clinical trials. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

Huge capital expenditure on vaccine development, the rising cost of research and development (R&D), biological and technical challenges associated with targeting more complex diseases, competition with better standards of care, the larger scale of clinical studies to prove safety and efficacy, and stringent regulations are the factors the market is expected to get hampered in the forecast period.

Industry Analysis

The therapeutic vaccines market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

Therapeutic Vaccines Market Segment Analysis

Tumor cell vaccine segment is expected to hold the largest market share in the therapeutic vaccines market.

The tumor cell vaccine segment accounted for the largest market share in 2021. Rising incidences of cancer leading to rising demand for the development of tumor cell vaccines is one of the dominating factors propelling the global therapeutic vaccines market. According to the National Cancer Institute, a tumor antigen vaccine is made of cancer cells, parts of cancer cells, or pure tumor antigens. The first allogeneic whole-cell vaccine was the Canvaxin, consisting of three melanoma lines combined with BCG as an adjuvant 16. After promising results in phase II clinical trials, it failed in two multi-institutional randomized phase III trials due to the immune system's inherent tolerance to several antigens. GVAX has proven more effective than others in inducing dendritic cells' recruitment, maturation, and function (DCs). This most potent antigen-presenting cell was evaluated for prostate, breast, and pancreatic cancer but failed due to strong anti-MHC immune reactions that can interfere with the anti-tumor response. Lucanix, which targets NSCLC, is in two independent phase 3 trials and has significantly improved overall survival in advanced diseases. 

Therapeutic Vaccine Market Scope

Metrics

Details

Market CAGR

12.63%

Segments Covered

By Type, By Disease Type, By Technology, By Distribution Channel, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

Therapeutic Vaccines Market Geographical Analysis

North American region is expected to hold the largest market share in the global therapeutic vaccines market.

North America accounted for the highest revenue share in 2021. The rising incidence of chronic infectious diseases, cancer, Alzheimer’s, are the factors to drive the market growth. For instance, according to the American Cancer Society, In 2020, an estimated 1.8 million new cancer cases and 606,520 cancer deaths in the United States will be diagnosed. In contrast, in 2021, an estimated 1.9 million new cancer cases will be diagnosed and 608,570 cancer deaths in the United States. Therefore, it has increased the adoption of therapeutic vaccines. Moreover, according to World Health Organization, in the United States of America, from 3 January 2020 to 12 September 2022, there have been 93,822,524 confirmed cases of COVID-19, with 1,038,273 deaths reported to WHO. As of 25 August 2022, 600,769,565 vaccine doses have been administered. The demand for more efficient vaccines is expected to rise, which may reduce the decrease of vaccines during disease outbreaks. Also, the presence of key manufacturers, increasing investments by pharmaceutical companies for vaccine development in the region, proactive government initiatives, favorable subsidiaries, and a large patient pool is driving the market in North America. For instance, recent estimates from the Congressional Research Service, the Government Accountability Office, and Chad Brown and Thomas Bollyky, as well as data from the GHIAA.org and Devex websites, place government spending at $18 billion to $23 billion. According to the Congressional Budget Office, the Biomedical Research and Development Authority (BARDA) has spent $19.3 billion on COVID-19 vaccine development alone. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Therapeutic Vaccines Market Competitive Landscape

Major key players in the therapeutic vaccines market are Bavarian Nordic, Biovest International, Celldex Therapeutics, Antigenics, Argos Therapeutics, Cel-Sci, Celtic Pharma, Curevac And Cytos Biotechnology, Pfizer, Affiris, GlaxoSmithKline, Merck & Co., Pfizer, Vaccinogen Inc. Sanofi Agenus Inc.

Bavarian Nordic A/S:

Overview:

Bavarian Nordic A/S is a fully integrated biotechnology firm that develops, manufactures, and commercializes vaccines for infectious illnesses and cancer immunotherapies. The company is headquartered in Hellerup, Denmark, with a production facility in Kvistgrd and an auxiliary location in Hrsholm. The company also has offices in Zug, Switzerland, and Morrisville, North Carolina, as well as a research and development facility in Martinsried, Germany. In its research and development, the company employs viral vectors.

­Product Portfolio:

Rabipur: Rabipur is a vaccine containing rabies virus that has been killed. After administration of the vaccine, the immune system (the body's natural defence system) forms antibodies to rabies viruses. These antibodies protect from infections or diseases by the virus that causes rabies.

Frequently Asked Questions

What is the Projected CAGR value of the Therapeutic Vaccines Market?

Therapeutic Vaccines Market is expected to grow at a CAGR of 12.63% during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America region Controls the Therapeutic Vaccines Market during 2022-2029

Which is the fastest growing region in the Therapeutic Vaccines Market?

Among all regions, Asia Pacific is the fastest growing market share during the forecast period 

Trending Topics

Therapeutic Beds Market

Hepatitis A Vaccine Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest